Focus Partners Wealth
BCRX icon

Focus Partners Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Focus Partners Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
+24,877
New +$225K ﹤0.01% 2371
2025
Q4 		– Sell
-10,117
Closed -$2.07M – 2663
2025
Q3 		$2.07M Buy
+10,117
New +$84.2K ﹤0.01% 1003

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Focus Partners Wealth's BCRX Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 24,877 shares worth $249K. The stake represents ﹤0.01% of the portfolio and ranks #2371 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in BCRX as recently as Q3 2025.

Focus Partners Wealth first reported a position in BCRX in Q3 2025 and has held it in 2 quarters since. The position peaked at $2.07M in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Focus Partners Wealth held 24,877 shares of BioCryst Pharmaceuticals worth $249K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Focus Partners Wealth position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2371 holding.
  • Focus Partners Wealth first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Focus Partners Wealth's BioCryst Pharmaceuticals position peaked at $2.07M in Q3 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.